Is Ideaya Biosciences Stock a Good Investment?
Ideaya Biosciences Investment Advice | IDYA |
- Examine Ideaya Biosciences' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Ideaya Biosciences' leadership team and their track record. Good management can help Ideaya Biosciences navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Ideaya Biosciences' business and its evolving consumer preferences.
- Compare Ideaya Biosciences' performance and market position to its competitors. Analyze how Ideaya Biosciences is positioned in terms of product offerings, innovation, and market share.
- Check if Ideaya Biosciences pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Ideaya Biosciences' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Ideaya Biosciences stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Ideaya Biosciences is a good investment.
Sell | Buy |
Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Ideaya Biosciences Stock
Researching Ideaya Biosciences' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 99.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 1.96. Some equities with similar Price to Book (P/B) outperform the market in the long run. Ideaya Biosciences recorded a loss per share of 2.33. The entity had not issued any dividends in recent years.
To determine if Ideaya Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Ideaya Biosciences' research are outlined below:
| Ideaya Biosciences generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 23.39 M. Net Loss for the year was (112.96 M) with loss before overhead, payroll, taxes, and interest of (38.6 M). | |
| Ideaya Biosciences currently holds about 268.62 M in cash with (115.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.83. | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer |
Ideaya Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Ideaya Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Ideaya Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 5th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 5th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Ideaya Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Ideaya Biosciences' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-02-20 | 2023-12-31 | -0.47 | -0.52 | -0.05 | 10 | ||
2022-05-10 | 2022-03-31 | -0.41 | -0.36 | 0.05 | 12 | ||
2023-08-10 | 2023-06-30 | -0.56 | -0.5 | 0.06 | 10 | ||
2023-05-09 | 2023-03-31 | -0.55 | -0.49 | 0.06 | 10 | ||
2023-03-07 | 2022-12-31 | -0.56 | -0.5 | 0.06 | 10 | ||
2021-03-23 | 2020-12-31 | -0.3 | -0.18 | 0.12 | 40 | ||
2019-11-13 | 2019-09-30 | -0.66 | -0.54 | 0.12 | 18 | ||
2024-08-06 | 2024-06-30 | -0.54 | -0.68 | -0.14 | 25 |
Know Ideaya Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Ideaya Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Ideaya Biosciences backward and forwards among themselves. Ideaya Biosciences' institutional investor refers to the entity that pools money to purchase Ideaya Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Adage Capital Partners Gp Llc | 2024-06-30 | 2.1 M | Geode Capital Management, Llc | 2024-09-30 | 1.9 M | Pictet Asset Manangement Sa | 2024-06-30 | 1.6 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.6 M | Bvf Inc | 2024-09-30 | 1.4 M | Avidity Partners Management Lp | 2024-09-30 | 1.4 M | Ra Capital Management, Llc | 2024-09-30 | 1.3 M | Fiera Capital Corporation | 2024-06-30 | 1.3 M | Sofinnova Ventures | 2024-06-30 | 1.2 M | Fmr Inc | 2024-09-30 | 12.6 M | Blackrock Inc | 2024-06-30 | 6.8 M |
Ideaya Biosciences' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.32 B.Market Cap |
|
Ideaya Biosciences' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.17) | (0.18) | |
| Return On Capital Employed | (0.22) | (0.23) | |
| Return On Assets | (0.17) | (0.18) | |
| Return On Equity | (0.18) | (0.17) |
Determining Ideaya Biosciences' profitability involves analyzing its financial statements and using various financial metrics to determine if Ideaya Biosciences is a good buy. For example, gross profit margin measures Ideaya Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Ideaya Biosciences' profitability and make more informed investment decisions.
Please note, the presentation of Ideaya Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Ideaya Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Ideaya Biosciences' management manipulating its earnings.
Evaluate Ideaya Biosciences' management efficiency
Ideaya Biosciences has return on total asset (ROA) of (0.1585) % which means that it has lost $0.1585 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.211) %, meaning that it created substantial loss on money invested by shareholders. Ideaya Biosciences' management efficiency ratios could be used to measure how well Ideaya Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of November 26, 2024, Return On Tangible Assets is expected to decline to -0.18. In addition to that, Return On Capital Employed is expected to decline to -0.23. At present, Ideaya Biosciences' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 422 M, whereas Non Currrent Assets Other are forecasted to decline to about 416.2 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 9.72 | 10.20 | |
| Tangible Book Value Per Share | 9.72 | 10.20 | |
| Enterprise Value Over EBITDA | (14.51) | (15.24) | |
| Price Book Value Ratio | 3.30 | 3.46 | |
| Enterprise Value Multiple | (14.51) | (15.24) | |
| Price Fair Value | 3.30 | 3.46 | |
| Enterprise Value | 1.9 B | 2 B |
The strategic vision of Ideaya Biosciences management plays a critical role in its financial performance. By evaluating this vision, we provide insights into the stock's growth potential.
Beta 0.858 |
Basic technical analysis of Ideaya Stock
As of the 26th of November, Ideaya Biosciences retains the Standard Deviation of 2.91, market risk adjusted performance of (0.30), and Risk Adjusted Performance of (0.12). Ideaya Biosciences technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Ideaya Biosciences' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ideaya Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ideaya Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ideaya Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ideaya Biosciences' Outstanding Corporate Bonds
Ideaya Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Ideaya Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Ideaya bonds can be classified according to their maturity, which is the date when Ideaya Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| IEX 2625 15 JUN 31 Corp BondUS45167RAH75 | View | |
| US45167RAG92 Corp BondUS45167RAG92 | View |
Understand Ideaya Biosciences' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Ideaya Biosciences' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.12) | |||
| Market Risk Adjusted Performance | (0.30) | |||
| Mean Deviation | 2.26 | |||
| Coefficient Of Variation | (583.99) | |||
| Standard Deviation | 2.91 | |||
| Variance | 8.49 | |||
| Information Ratio | (0.22) | |||
| Jensen Alpha | (0.71) | |||
| Total Risk Alpha | (0.97) | |||
| Treynor Ratio | (0.31) | |||
| Maximum Drawdown | 15.21 | |||
| Value At Risk | (5.09) | |||
| Potential Upside | 4.15 | |||
| Skewness | (0.50) | |||
| Kurtosis | 0.884 |
| Risk Adjusted Performance | (0.12) | |||
| Market Risk Adjusted Performance | (0.30) | |||
| Mean Deviation | 2.26 | |||
| Coefficient Of Variation | (583.99) | |||
| Standard Deviation | 2.91 | |||
| Variance | 8.49 | |||
| Information Ratio | (0.22) | |||
| Jensen Alpha | (0.71) | |||
| Total Risk Alpha | (0.97) | |||
| Treynor Ratio | (0.31) | |||
| Maximum Drawdown | 15.21 | |||
| Value At Risk | (5.09) | |||
| Potential Upside | 4.15 | |||
| Skewness | (0.50) | |||
| Kurtosis | 0.884 |
Consider Ideaya Biosciences' intraday indicators
Ideaya Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Ideaya Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 78664.51 | |||
| Daily Balance Of Power | (0.17) | |||
| Rate Of Daily Change | 0.99 | |||
| Day Median Price | 27.01 | |||
| Day Typical Price | 26.85 | |||
| Price Action Indicator | (0.59) | |||
| Period Momentum Indicator | (0.25) |
Ideaya Biosciences Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 4th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 27th of September 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
| 10th of July 2024 Other Reports | ViewVerify |
Ideaya Stock media impact
Far too much social signal, news, headlines, and media speculation about Ideaya Biosciences that are available to investors today. That information is available publicly through Ideaya media outlets and privately through word of mouth or via Ideaya internal channels. However, regardless of the origin, that massive amount of Ideaya data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Ideaya Biosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Ideaya Biosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Ideaya Biosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Ideaya Biosciences alpha.
Ideaya Biosciences Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Ideaya Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Ideaya Biosciences Historical Investor Sentiment
Investor biases related to Ideaya Biosciences' public news can be used to forecast risks associated with an investment in Ideaya. The trend in average sentiment can be used to explain how an investor holding Ideaya can time the market purely based on public headlines and social activities around Ideaya Biosciences. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Ideaya Biosciences' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Ideaya Biosciences and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Ideaya Biosciences news discussions. The higher the estimate score, the more favorable the investor's outlook on Ideaya Biosciences.
Ideaya Biosciences Corporate Management
| Mick OQuigley | Chief Development | Profile | |
| Stu Dorman | Chief Officer | Profile | |
| Paul Stone | CFO VP | Profile | |
| JD Esq | Chief Secretary | Profile | |
| Matthew MD | VP Oncology | Profile | |
| Esq JD | Gen VP | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ideaya Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For information on how to trade Ideaya Stock refer to our How to Trade Ideaya Stock guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ideaya Biosciences. If investors know Ideaya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ideaya Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.33) | Revenue Per Share 0.051 | Quarterly Revenue Growth (0.03) | Return On Assets (0.16) | Return On Equity (0.21) |
The market value of Ideaya Biosciences is measured differently than its book value, which is the value of Ideaya that is recorded on the company's balance sheet. Investors also form their own opinion of Ideaya Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Ideaya Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ideaya Biosciences' market value can be influenced by many factors that don't directly affect Ideaya Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Ideaya Biosciences' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Ideaya Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ideaya Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.